Next Article in Journal
Research on the Influence of Information Diffusion on the Transmission of the Novel Coronavirus (COVID-19)
Next Article in Special Issue
Time-Trends of Drug-Drug Interactions among Elderly Outpatients in the Piedmont Region (Italy): A Population-Based Study
Previous Article in Journal
Non-Cooperation within a School-Based Wellness Program during the COVID-19 Pandemic—A Qualitative Research
Previous Article in Special Issue
Multiple Medication Adherence and Related Outcomes in Community-Dwelling Older People on Chronic Polypharmacy: A Retrospective Cohort Study on Administrative Claims Data
 
 
Article

Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks

1
Unit of Medical Statistics, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
2
Unit of Gastroenterology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
3
Unit of Rheumatology, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
4
CESP, U1018 INSERM, Université Paris-Saclay, UVSQ, Hôpital Paul Brousse Bâtiment 15/16, CEDEX, 94807 Villejuif, France
5
Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy
6
Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, 56126 Pisa, Italy
7
Tuscan Regional Healthcare Agency, 50141 Florence, Italy
*
Author to whom correspondence should be addressed.
Academic Editors: Carlotta Franchi, Manuela Casula and Ilaria Ardoino
Int. J. Environ. Res. Public Health 2022, 19(11), 6799; https://doi.org/10.3390/ijerph19116799
Received: 12 April 2022 / Revised: 18 May 2022 / Accepted: 31 May 2022 / Published: 2 June 2022
(This article belongs to the Special Issue New Perspectives in Real-World Pharmacoepidemiology and Drug Safety)
Our study aims at providing evidence on patterns of use of biologic drugs for psoriasis in Tuscany, Italy. We conducted a drug-utilization study based on administrative databanks of Tuscany (EUPAS45365) from 2011 to 2019. We selected new users of etanercept, infliximab, adalimumab, ustekinumab, or secukinumab between 1 January 2011 and 31 December 2016. We considered subjects with psoriasis and followed subjects until the end of the study period (three years after the first dispensation of biologic drug for psoriasis) or the patient’s death, whichever came first. We censored subjects for pregnancy or neoplasia. For each subject, we defined the state as the weekly coverage of one of the biologic drugs of interest. We then defined the switch as the change from a state to another one. A total of 7062 subjects with a first dispensation of a PSObio drug in the inclusion period was identified, and 1839 (52.9% female, 51.6 mean age) patients were included in the analysis. Among new users of adalimumab (N = 770, 41.9%), one third showed a continuous behaviour whereas the others moved to etanercept and ustekinumab. New users of etanercept (N = 758, 41.2%), had the highest proportion of switchers, with adalimumab most often being the second choice. New users of infliximab (N = 159, 8.6%) experienced the highest proportion of treatment discontinuation. The present study suggests that the majority of patients treated with PSObio drugs do not switch from one active ingredient to another. However, patients who started biological therapy with etanercept had the highest frequency of switching to other PSObio drugs, whereas those who started with secukinumab or ustekinumab had the lowest. View Full-Text
Keywords: psoriasis; switching; biologics; drug utilization psoriasis; switching; biologics; drug utilization
Show Figures

Figure 1

MDPI and ACS Style

Giometto, S.; Tillati, S.; Baglietto, L.; De Bortoli, N.; Mosca, M.; Conte, M.; Tuccori, M.; Gini, R.; Lucenteforte, E. Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. Int. J. Environ. Res. Public Health 2022, 19, 6799. https://doi.org/10.3390/ijerph19116799

AMA Style

Giometto S, Tillati S, Baglietto L, De Bortoli N, Mosca M, Conte M, Tuccori M, Gini R, Lucenteforte E. Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks. International Journal of Environmental Research and Public Health. 2022; 19(11):6799. https://doi.org/10.3390/ijerph19116799

Chicago/Turabian Style

Giometto, Sabrina, Silvia Tillati, Laura Baglietto, Nicola De Bortoli, Marta Mosca, Marco Conte, Marco Tuccori, Rosa Gini, and Ersilia Lucenteforte. 2022. "Use of Biological Drugs for Psoriasis: A Drug-Utilization Study Using Tuscan Administrative Databanks" International Journal of Environmental Research and Public Health 19, no. 11: 6799. https://doi.org/10.3390/ijerph19116799

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop